Arbutus 与中国齐鲁达成高达 3 亿美元的乙肝候选药物交易；

StephenW

Arbutus 与中国齐鲁达成高达 3 亿美元的乙肝候选药物交易； 股价上涨 7%
2021 年 12 月 13 日上午 8:33 ETArbutus Biopharma Corporation (ABUS)
作者：乔纳森·M·布洛克
, SA 新闻编辑

     Arbutus Biopharma（纳斯达克股票代码：ABUS）和齐鲁制药已就前者的 AB-729治疗乙型肝炎（“HBV”）在中国、香港、澳门和台湾达成了许可协议和合作伙伴关系。
     条款要求 Arbutus 获得 4000 万美元的预付款和 1500 万美元的股权投资。 该公司还有资格获得高达 2.45 亿美元的里程碑付款，以及高达 20% 的两位数分层特许权使用费。
     AB-729 是一种 RNAi 治疗剂，旨在减少所有 HBV 病毒蛋白和抗原。

Arbutus in up to $300M deal with Qilu in China for hepatitis B candidate; shares up 7%
Dec. 13, 2021 8:33 AM ETArbutus Biopharma Corporation (ABUS)
By: Jonathan M Block
, SA News Editor

    Arbutus Biopharma (NASDAQ:ABUS) and Qilu Pharmaceutical have brokered a licensing agreement and partnership for the former's AB-729 for hepatitis B ("HBV") in China, Hong Kong, Macau, and Taiwan.
    Terms call for Arbutus to receive $40M upfront and a $15M equity investment. The company is also eligible for milestone payments up to $245M, as well as double-digit tiered royalties up to the low twenties percent.
    AB-729 is a RNAi therapeutic designed to reduce all HBV viral proteins and antigens.